ACS Medicinal Chemistry Letters
Letter
of the cystic fibrosis gene: genetic analysis. Science 1989, 245, 1073−
T.; Rowe, S. M. VX-659TexacaftorIvacaftor in patients with
cystic fibrosis and one or two Phe508del Alleles. N. Engl. J. Med. 2018,
379, 1599−1611.
(19) Vertex Selects Triple Combination Regimen of Vx-445, Tezacaftor
1
080.
(
3) Welsh, M. J.; Smith, A. E. Molecular mechanisms of CFTR
chloride channel dysfunction in cystic fibrosis. Cell 1993, 73, 1251−
254.
4) Zielenski, J.; Tsui, L. C. Cystic fibrosis: genotypic and
phenotypic variations. Annu. Rev. Genet. 1995, 29, 777−807.
5) Marinko, J. T.; Huang, H.; Penn, W. D.; Capra, J. A.; Schlebach,
1
(
(
J. P.; Sanders, C. R. Folding and misfolding of human membrane
proteins in health and disease: from single molecules to cellular
proteostasis. Chem. Rev. 2019, 119, 5537−5606.
(20) Wang, X.; Liu, B.; Searle, X.; Yeung, C.; Bogdan, A.; Greszler,
S.; Singh, A.; Fan, Y.; Swensen, A. M.; Vortherms, T.; Balut, C.; Jia,
Y.; Desino, K.; Gao, W.; Yong, H.; Tse, C.; Kym, P. Discovery of 4-
[(2R,4R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]-
carbonyl}amino)-7-(difluoromethoxy)-3,4-dihydro-2H-chromen-2-
yl]benzoic acid (ABBV/GLPG-2222), a potent cystic fibrosis
transmembrane conductance regulator (CFTR) corrector for the
treatment of cystic fibrosis. J. Med. Chem. 2018, 61, 1436−1449.
(21) Ehrhardt, C.; Collnot, E. M.; Baldes, C.; Becker, U.; Laue, M.;
Kim, K. J.; Lehr, C. M. Towards an in vitro model of cystic fibrosis
small airway epithelium: Characterisation of the human bronchial
epithelial cell line CFBE41o. Cell Tissue Res. 2006, 323, 405−415.
(
6) Lukacs, G. L.; Verkman, A. S. CFTR: folding, misfolding and
correting the ΔF508 conformational defect. Trends Mol. Med. 2012,
1
(
8, 81−91.
7) Pasyk, E. A.; Foskett, J. K. Mutant (ΔF508) cystic fibrosis
−
transmembrane conductance regulator Cl channel is functional when
retained in endoplasmic reticulum of mammalian cells. J. Biol. Chem.
1
(
995, 270, 12347−12350.
8) Veit, G.; Avramescu, R. G.; Chiang, A. N.; Houck, S. A.; Cai, Z.;
Peters, K. W.; Hong, J. S.; Pollard, H. B.; Guggino, W. B.; Balch, W.
E.; Skach, W. R.; Cutting, G. R.; Frizzell, R. A.; Sheppard, D. N.; Cyr,
D. M.; Sorscher, E. J.; Brodsky, J. L.; Lukacs, G. L. From CFTR
biology toward combinatorial pharmacotherapy: expanded classifica-
tion of cystic fibrosis mutations. Mol. Biol. Cell 2016, 27, 424−433.
(22) Veit, G.; Avramescu, R. G.; Perdomo, D.; Phuan, P. W.;
Bagdany, M.; Apaja, P. M.; Borot, F.; Szollosi, D.; Wu, Y. S.;
Finkbeiner, W. E.; Hegedus, T.; Verkman, A. S.; Lukacs, G. L. Some
gating potentiators, including VX-770, diminish deltaF508-CFTR
functional expression. Sci. Transl. Med. 2014, 6, 246ra97.
(
9) Rowe, S. M.; Verkman, A. S. Cystic fibrosis transmembrane
(23) Vu, C. B.; Bridges, R. J.; Pena-Rasgado, C.; Lacerda, A. E.;
regulator correctors and potentiators. Cold Spring Harbor Perspect.
Med. 2013, 3, a009761.
Bordwell, C.; Sewell, A.; Nichols, A. J.; Chandran, S.; Lonkar, P.;
Picarella, D.; Ting, A.; Wensley, A.; Yeager, M.; Liu, F. Fatty acid
cysteamine conjugates as novel and potent autophagy activators that
enhance the correction of misfolded F508del-cystic fibrosis trans-
membrane conductance regulator (CFTR). J. Med. Chem. 2017, 60,
(
10) Spano, V.; Montalbano, A.; Carbone, A.; Scudieri, P.; Galietta,
L. J. V.; Barraja, P. An overview on chemical structures as ΔF508-
CFTR correctors. Eur. J. Med. Chem. 2019, 180, 430−448.
(
11) Wainwright, C. E.; Elborn, J. S.; Ramsey, B. W.; Marigowda, G.;
4
(
58−473.
Huang, X.; Cipolli, M.; Colombo, C.; Davies, J. C.; De Boeck, K.;
Flume, P. A.; Konstan, M. W.; McColley, S. A.; McCoy, K.; McKone,
E. F.; Munck, A.; Ratjen, F.; Rowe, S. M.; Waltz, D.; Boyle, M. P.
Lumacaftor-Ivacaftor in patients with cystic fibrosis homozygous for
Phe508del CFTR. N. Engl. J. Med. 2015, 373, 220−231.
24) Van der Plas, S. E.; Kelgtermans, H.; De Munck, T.; Martina, S.
L. X.; Dropsit, S.; Quinton, E.; De Blieck, A.; Joannesse, C.;
Tomaskovic, L.; Jans, M.; Christophe, T.; van der Aar, E.; Borgonovi,
M.; Nelles, L.; Gees, M.; Stouten, p.; Van Der Schueren, J.;
Mammoliti, O.; Conrath, K.; Andrews, M. Discovery of N-(3-
carbamoyl-5,5,7,7-tetramethyl-5,7-dihydro-4H-thieno[2,3-c]pyran-2-
yl)-lH-pyrazole-5-carboxamide (GLPG1837), a novel potentiator
which can open class III mutant cystic fibrosis transmembrane
conductance regulator (CFTR) channels to a high extent. J. Med.
Chem. 2018, 61, 1425−1435.
(
12) Van Goor, F.; Hadida, S.; Grootenhuis, P. D.; Burton, B.; Stack,
J. H.; Straley, K. S.; Decker, C. J.; Miller, M.; McCartney, J.; Olson, E.
R.; Wine, J. J.; Frizzell, R. A.; Ashlock, M.; Negulescu, P. A.
Correction of the F508del-CFTR protein processing defect in vitro by
the investigational drug VX-809. Proc. Natl. Acad. Sci. U. S. A. 2011,
1
(
08, 18843−18848.
(25) Van Goor, F.; Hadida, S.; Grootenhuis, P. D.; Burton, B.; Cao,
13) Van Goor, F.; Hadida, S.; Grootenhuis, P. D.; Burton, B.; Cao,
D.; Neuberger, T.; Turnbull, A.; Singh, A.; Joubran, J.; Hazlewood, A.;
Zhou, J.; McCartney, J.; Arumugam, V.; Decker, C.; Yang, J.; Young,
C.; Olson, E. R.; Wine, J. J.; Frizzell, R. A.; Ashlock, M.; Negulescu, P.
Rescue of CF airway epithelial cell function in vitro by a CFTR
potentiator, VX-770. Proc. Natl. Acad. Sci. U. S. A. 2009, 106, 18825−
D.; Neuberger, T.; Turnbull, A.; Singh, A.; Joubran, J.; Hazlewood, A.;
Zhou, J.; McCartney, J.; Arumugam, V.; Decker, C.; Yang, J.; Young,
C.; Olson, E. R.; Wine, J. J.; Frizzell, R. A.; Ashlock, M.; Negulescu, P.
Rescue of CF airway epithelial cell function in vitro by a CFTR
potentiator, VX-770. Proc. Natl. Acad. Sci. U. S. A. 2009, 106, 18825−
1
(
8830.
1
(
8830.
14) Donaldson, S. H.; Pilewski, J. M.; Griese, M.; Cooke, J.;
26) Altenbach, R. J.; Bogdan, A.; Desroy, N.; Greszler, S. N.;
Koenig, J. R.; Kym, P. R.; Liu, B.; Scanio, M. J.; Searle, X. B.; Wang,
X.; Yeung, M. C.; Zhao, G. Substituted Pyrrolidines and Method of
Use. U.S. Patent Appl. 20180099932, April 12, 2018.
Viswanathan, L.; Tullis, E.; Davies, J. C.; Lekstrom-Himes, J. A.;
Wang, L. T. Tezacaftor/Ivacaftor in subjects with cystic fibrosis and
F508del/F508del-CFTR or F508del/G551D-CFTR. Am. J. Respir.
Crit. Care Med. 2018, 197, 214−224.
(
27) Hashimoto, T.; Maruoka, K. Recent advances of catalytic
asymmetric 1,3-dipolar cycloadditions. Chem. Rev. 2015, 115, 5366−
412.
28) Hartung, J.; Greszler, S. N.; Klix, R. C.; Kallemeyn, J. M.
(
15) Li, H.; Pesce, E.; Sheppard, D. N.; Singh, A. K.; Pedemonte, N.
5
(
Therapeutic approaches to CFTR dysfunction: From discovery to
drug development. J. Cystic Fibrosis 2018, 17, S14−S21.
Development of an Enantioselective [3 + 2] cycloaddition to
(
16) Holguin, F. H. Triple CFTR modulator therapy for cystic
fibrosis. N. Engl. J. Med. 2018, 379, 1671−1672.
(
17) Keating, D.; Marigowda, G.; Burr, L.; Daines, C.; Mall, M. A.;
McKone, E. F.; Ramsey, B. W.; Rowe, S. M.; Sass, L. A.; Tullis, E.;
McKee, C. M.; Moskowitz, S. M.; Robertson, S.; Savage, J.; Simard,
C.; Van Goor, F.; Waltz, D.; Xuan, F.; Young, T.; Taylor-Cousar, J. L.
VX-445TezacaftorIvacaftor in patients with cystic fibrosis and
one or two Phe508del Alleles. N. Engl. J. Med. 2018, 379, 1612−1620.
(
18) Davies, J. C.; Moskowitz, S. M.; Brown, C.; Horsley, A.; Mall,
M. A.; McKone, E. F.; Plant, B. J.; Prais, D.; Ramsey, B. W.; Taylor-
Cousar, J. L.; Tullis, E.; Uluer, A.; McKee, C. M.; Robertson, S.;
Shilling, R. A.; Simard, C.; Van Goor, F.; Waltz, D.; Xuan, F.; Young,
F
ACS Med. Chem. Lett. XXXX, XXX, XXX−XXX